Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day streak of losses despite Middle East clashes
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
December 4, 2024 6:54 AM ESTChardan Capital Markets analyst Geulah Livshits raised the price target on Senti Biosciences, Inc. (NASDAQ: SNTI) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "On 3 December, Senti Biosciences hosted a call to discuss initial data from the phase I trial of its... More
